This is the authors' abstract. We don't add key points for this paper.
Background Immunosuppression caused by tumorigenesis may promote tumor progress and invasion. Here, we investigated whether the characteristics of circulating T lymphocyte subtypes in patients with extensive small cell lung cancer (ED-SCLC) can be used as an alternative marker of tumor progression. Methods This study included 36 newly diagnosed ED-SCLC patients before treatment and the patients were followed up. 22 age and sex-matched healthy volunteers were selected as control. The percentages and proliferation potential of T lymphocyte subpopulations from peripheral blood were measured. Results CD4 + CD25 + Foxp3 + regulatory T cells (Tregs) were elevated in ED-SCLC patients compared with healthy controls ( p = 0.0083). In contrast, the percentages of CD3 + and CD3 + CD4 + T cells were significantly lower in SCLC patients ( p < 0.001; p = 0.0014). The proliferation (%divided) of CD8 + T cells of SCLC patients was suppressed compared with healthy controls ( p = 0.0058), but not of CD4 + T cells ( p = 0.1611). Multivariate analyses showed that the %divided of CD8 + T cells is an independent predictor for PFS (HR: 4.342, 95% CI 1.324–14.245; p = 0.015). The percentages of peripheral Tregs and the degree of chemotherapy or radiotherapy induced lymphopenia negatively correlated with the proliferation of CD8 + T cells ( p = 0.0225, r = − 0.379; p = 0.0003, r = − 0.464). Conclusion The present study indicates that SCLC patients have impaired immunity in peripheral blood, and the proliferation potential of circulating CD8 + T cells is a significant predicator for PFS.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
An et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: